Clinical Trials Directory

Trials / Terminated

TerminatedNCT00771134

Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study of Lu AA39959 in the Treatment of Depression in Patients With Bipolar I or II Disorder

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
105 (actual)
Sponsor
H. Lundbeck A/S · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the efficacy and safety of Lu AA39959 in the treatment of depression in patients with bipolar disorder.

Detailed description

Bipolar disorder is a common lifelong psychiatric disorder characterized by recurrent mood swings with manic or hypomanic episodes alternated with depressive episodes of longer duration. Patients spend more time in depression than in (hypo)mania over their life time. The main goals for the treatment of bipolar disorder are resolution of symptoms, return to premorbid level of social functioning and prevention of future episodes. Although there are many treatments for bipolar disorder, few are approved, and they have limitations in their use due to safety and tolerability issues. Recommendations exist to use mood stabilisers, antipsychotics or a combination thereof with or without antidepressants and the polypharmacy employed in many cases is a reason for concern. There is a major medical need for more effective treatments in monotherapy with a reduced potential for adverse effects. This study evaluates the efficacy and safety of the new drug, Lu AA39959, in treatment of depression in patients with bipolar disorder.

Conditions

Interventions

TypeNameDescription
DRUGLu AA3995930mg/day; 15mg B.I.D. for 8 weeks
DRUGPlaceboB.I.D. for 8 weeks
DRUGQuetiapine300mg/day for 8 weeks

Timeline

Start date
2008-12-01
Primary completion
2009-06-01
Completion
2009-08-01
First posted
2008-10-13
Last updated
2014-05-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00771134. Inclusion in this directory is not an endorsement.